Bergamo Lymphoid Cancer Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Patient registry.
- Who it may be relevant to
- Registry conditions: Hodgkin Lymphoma, Non Hodgkin Lymphoma, Myeloma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This registry has been established to gain a better understanding of the clinical and biological characteristics and outcome of patients with lymphoid cancer
Detailed description
Lymphoid cancer including Hodgkin disease, non-Hodgkin lymphomas (NHL) and myeloma, represents the most common hematologic malignancy. Despite the overall prognosis improved in the last 10 years, there are many open issues that need to be addressed, specifically refractoriness to standard treatment, disease recurrence and outcome with new drug in the so called "real world" setting. Since the Hematology and Bone Marrow Transplant Unit at "Ospedale Papa Giovanni XIII" of Bergamo has developed specific tools to collect clinical data thought fully validated electronic charts and biological specimens thanks to a regulatory compliant biobanking program, the aim of this study is to collect clinical and biological information of lymphoid cancer patients. The cohort of patients enrolled will permit to analyze the practice pattern, perform biological correlative studies of great translational potential with relevance to clinical practice.
Interventions
- Other Patient registry
Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
Primary outcome measures
- Overall survival [Time frame: 20 years]
Secondary outcome measures (3)
- Disease-free survival [Time frame: 20 years]
- Progression-free survival [Time frame: 20 years]
- Biological correlative studies [Time frame: 20 years]
Eligibility criteria
Inclusion criteria
- Male or female patients 18 years or older
- Written informed consent
- Confirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Exclusion criteria
\- Unconfirmed diagnosis of Hodgkin disease, non-Hodgkin lymphomas or myeloma
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Italy · 1 center
- Hematology and Bone Marrow Transplant Unit, A.O. Ospedale Papa Giovanni XXIII — Bergamo
Identifiers
NCT: NCT03131531 · BLCR